Health Advocates Demand U-Turn In EU Trade Policy To Align With Its Health Objectives

FLickr -  Greg McMullin -

Health Action International Europe, and Oxfam today issued a briefing paper entitled, “Trading Away Access to Medicines: How the European trade agenda continues to undermine access to medicines.” The paper argues that new concerns such as the ebola virus and the threat of unchecked antimicrobial resistance show the need for a new model for financing pharmaceutical research and development.

Panellists Discuss Value Of Patent Pooling For HIV/AIDS, Potential For Other Diseases

MPP's Greg Perry speaks, flanked by Duneston (left), Mirza (right), and other panellists

A side event to this week’s World Intellectual Property Organization annual General Assembly highlighted the work of the Geneva-based Medicines Patent Pool in fighting HIV/AIDS, and discussed whether it makes sense for the patent pool model to be extended to other diseases.

Gilead Monopoly Prevails Over Non-Discriminatory Access As Debated Hepatitis C Deal Sets Off

Cost of Medicines

Gilead on 15 September struck voluntary licence deals with seven India-based generic manufacturers to expand access to its hepatitis C innovative drugs in developing countries. With a limited territory covered, this, yet deserving, pact raises doubts about the coherence of Indian counterparts at a time when there are no relevant patents in India, several pre-grant oppositions have been filed and unrestrained competition by compulsory licences could have been pursued.

Guest Post: Nine Mandatory Licences Allow Greater Access To Medicines In Ecuador

Health 1

What is a mandatory licence? Mandatory licenses are a legal remedy within the intellectual property flexibilities provided by the World Trade Organization allowing a government to grant permission to third parties to produce a patented product or use a patented process without the consent of the patentee, in order to address a priority status for the country.

WHO: Fight Ebola Now, Solve Patent Issues Later

WHO Ebola Briefing - Sept 2014

The world and the global health community have been taken by surprise by the worst outbreak of Ebola so far. The World Health Organization today (5 September) said a vaccine could be available in November 2014 if proven safe. So far, according to the WHO, intellectual property issues have not acted as a barrier to accessing potential treatments and vaccines, and the focus for now is on emergency measures to find health solutions.

Biosimilar Medicines Need Strong Regulation, IP Crucial For Innovation, Pharma Says

Biosimilar medicines might prove to be a new reservoir for innovation for the pharmaceutical industry. However, the complexity of their manufacture needs a stringent regulatory framework, according to the industry.

WHO Raises Its Voice To Underline Health Effects Of Climate Change

The World Health Organization this week is holding its first conference on health and climate change. The major objective of the conference is to raise awareness on the impact of climate change on health, according to the WHO, which said it aims to strengthen its voice in the debate.

Market Failure, Not IP, The Issue In Ebola Treatment Shortage, WHO Says

Faced with the worst outbreak of Ebola since its discovery some 40 years ago, the world is scrambling for treatments. A World Health Organization-convened panel of experts has decided it is ethical to use experimental treatments. Why is there no treatment available even after 40 years? Market failure, not intellectual property rights, says the WHO.